Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-based IBDSL Cohort

S.F.G. Jeuring, P.H.A. Bours, M.P. Zeegers, T.W. Ambergen, T.R.A. van den Heuvel, M.J.L. Romberg-Camps, A.A. van Bodegraven, L.E. Oostenburg, S.O. Breukink, L.P.S. Stassen, W.H. Hameeteman, A.A.M. Masclee, D.M.A.E. Jonkers, M.J. Pierik

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Background and Aims: In the past decades, treatment options and strategies for ulcerative colitis [UC] have radically changed. Whether these developments have altered the disease outcome at population level is yet unknown. Therefore, we evaluated the disease outcome of UC over the past two decades in the South-Limburg area of The Netherlands. Methods: In the Dutch population-based IBDSL cohort, three time cohorts were defined: cohort 1991-1997 [cohort A], cohort 1998-2005 [cohort B], and cohort 2006-2010 [cohort C]. The colectomy and hospitalisation rates were compared between cohorts by Kaplan-Meier survival analyses. Hazard ratios [HR] for early colectomy [within 6 months after diagnosis], late colectomy [beyond 6 months after diagnosis], and hospitalisation were calculated using Cox regression models. Results: In total, 476 UC patients were included in cohort A, 587 patients in cohort B, and 598 patients in cohort C. Over time, an increase in the use of immunomodulators [8.1%, 22.8% and 21.7%, respectively, p time.
Original languageEnglish
Pages (from-to)837-845
JournalJournal of Crohn's & Colitis
Volume9
Issue number10
DOIs
Publication statusPublished - 1 Jan 2015

Cite this